^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    15d
    B-free Multistage Trial (clinicaltrials.gov)
    P4, N=210, Enrolling by invitation, Insel Gruppe AG, University Hospital Bern | Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Nov 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
    15d
    Multifaceted impact of HIV inhibitor dapivirine on triple negative breast cancer cells reveals potential entities as targets for novel therapy. (PubMed, Sci Rep)
    Here we show the potent impact of dapivirine on MDA-MB-231 TNBC cells, while NNRTI like nevirapine showed marginal effects...Taken together, dapivirine exhibits the potential to be considered as a repurposed drug for TNBC as monotherapy/combination therapy. Notably, it could also potentially be a treatment for individuals with dual ailments, such as HIV and TNBC, if the clinical outcomes with dapivirine for TNBC become favorable.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • TCF3 (Transcription Factor 3) • PCNA (Proliferating cell nuclear antigen)
    |
    HER-2 amplification • EGFR amplification
    23d
    Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, The Miriam Hospital
    New trial
    29d
    CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy (clinicaltrials.gov)
    P1/2, N=45, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2026 --> Jan 2028 | Initiation date: Sep 2024 --> May 2025 | Trial primary completion date: Dec 2026 --> Jan 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    1m
    CROWN: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (clinicaltrials.gov)
    P3, N=324, Not yet recruiting, ViiV Healthcare
    New P3 trial • Head-to-Head
    1m
    CABO-LA: Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Pontificia Universidad Catolica de Chile | Trial completion date: Apr 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • HEOR
    1m
    PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel (clinicaltrials.gov)
    P1/2, N=40, Completed, International Partnership for Microbicides, Inc. | Active, not recruiting --> Completed
    Trial completion
    2ms
    ELDORADO: DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (clinicaltrials.gov)
    P3, N=610, Not yet recruiting, ANRS, Emerging Infectious Diseases | Trial completion date: Apr 2027 --> Nov 2027 | Initiation date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2026 --> Nov 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Head-to-Head
    2ms
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=180, Recruiting, ViiV Healthcare | N=60 --> 180
    Enrollment change
    2ms
    LOVER60: Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 (clinicaltrials.gov)
    P4, N=120, Not yet recruiting, Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
    New P4 trial
    |
    CD4 (CD4 Molecule)
    2ms
    The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV (clinicaltrials.gov)
    P=N/A, N=164, Not yet recruiting, MetroHealth Medical Center
    New trial
    2ms
    A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Janssen Sciences Ireland UC | Trial primary completion date: Dec 2030 --> Jun 2027
    Trial primary completion date • Combination therapy
    2ms
    DORASPEP: "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" (clinicaltrials.gov)
    P=N/A, N=226, Completed, Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Active, not recruiting --> Completed
    Trial completion
    3ms
    IMPALA: Improving HIV-1 Control in Africa with Long Acting Antiretrovirals (clinicaltrials.gov)
    P3, N=540, Active, not recruiting, MRC/UVRI and LSHTM Uganda Research Unit | Recruiting --> Active, not recruiting | Phase classification: P3b --> P3 | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Apr 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    3ms
    Efavirenz: New Hope in Cancer Therapy. (PubMed, Cureus)
    In addition to its anti-cancer properties, efavirenz has the advantage of being a well-established and relatively inexpensive medication with a favorable safety profile. If proven effective, efavirenz could offer a cost-effective therapeutic option, which is an intriguing direction that warrants further investigation.
    Review • Journal
    |
    FASN (Fatty acid synthase)
    3ms
    Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics (clinicaltrials.gov)
    P1/2, N=20, Recruiting, ViiV Healthcare | Trial completion date: Jun 2027 --> May 2028 | Trial primary completion date: Jul 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    3ms
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=60, Recruiting, ViiV Healthcare | Trial primary completion date: Feb 2026 --> Oct 2026
    Trial primary completion date
    3ms
    Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers (clinicaltrials.gov)
    P1, N=24, Completed, Chelsea and Westminster NHS Foundation Trust | N=14 --> 24
    Enrollment change
    3ms
    TLATOANI: Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI (clinicaltrials.gov)
    P4, N=108, Recruiting, Instituto Mexicano del Seguro Social
    New P4 trial
    4ms
    Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women (clinicaltrials.gov)
    P1, N=10, Recruiting, University of North Carolina, Chapel Hill | Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    4ms
    SUPLA: Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals (clinicaltrials.gov)
    P3, N=40, Recruiting, Chang Gung Memorial Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Adherence
    4ms
    The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (clinicaltrials.gov)
    P3, N=310, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2026 | Trial primary completion date: Jun 2025 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    4ms
    Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    CABO-CHANCE: A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV (clinicaltrials.gov)
    P=N/A, N=287, Active, not recruiting, University Hospital Virgen de las Nieves
    New trial
    5ms
    SUPLA: Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals (clinicaltrials.gov)
    P3, N=40, Not yet recruiting, Chang Gung Memorial Hospital
    New P3 trial • Adherence
    5ms
    PUSH: Peer Behavioral Activation Utilization to Address Structural Racism and Discrimination and Improve HIV Outcomes in High-Risk, Substance-Using Populations (clinicaltrials.gov)
    P=N/A, N=186, Not yet recruiting, University of Maryland, Baltimore
    New trial
    6ms
    Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy (clinicaltrials.gov)
    P3, N=1105, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | Phase classification: P3b --> P3
    Trial completion • Phase classification
    6ms
    PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, International Partnership for Microbicides, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    6ms
    Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008 (clinicaltrials.gov)
    P1, N=124, Completed, International Partnership for Microbicides, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Jul 2024
    Trial completion • Trial completion date
    6ms
    Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study (clinicaltrials.gov)
    P3, N=93, Completed, ViiV Healthcare | Trial primary completion date: Apr 2023 --> Sep 2023
    Trial primary completion date • Patient reported outcomes
    6ms
    Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov)
    P1, N=49, Completed, Gilead Sciences | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Mar 2024 | Trial primary completion date: Mar 2027 --> Mar 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    6ms
    Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV. (PubMed, AIDS)
    Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.
    Journal
    |
    ER (Estrogen receptor)
    6ms
    EPIC: Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (clinicaltrials.gov)
    P4, N=108, Completed, University of Alabama at Birmingham | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    6ms
    A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants (clinicaltrials.gov)
    P1, N=126, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    6ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Recruiting, University of Nebraska | Not yet recruiting --> Recruiting
    Enrollment open • Adherence
    6ms
    Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study (clinicaltrials.gov)
    P2, N=97, Completed, ViiV Healthcare | Phase classification: P2b --> P2
    Phase classification
    6ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Not yet recruiting, University of Nebraska
    New trial • Adherence
    6ms
    Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov)
    P1/2, N=90, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2026 --> Jul 2027 | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    7ms
    Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov)
    P1, N=49, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting | N=110 --> 49 | Trial completion date: Dec 2024 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    7ms
    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=60, Recruiting, ViiV Healthcare | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    7ms
    GLACIER: Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (clinicaltrials.gov)
    P4, N=44, Completed, ViiV Healthcare | Active, not recruiting --> Completed
    Trial completion
    7ms
    The use of PD-1 functional knockout rats to study idiosyncratic adverse reactions to nevirapine. (PubMed, Toxicol Sci)
    The treated PD-1m/m rats developed more severe liver injury than PD-1-/- mice, but in contrast to expectations, they did not develop a skin rash. Functional knockouts provide a unique tool to study the mechanisms of IDRs.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)